25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PHAXIAM Therapeutics S.A.
Buy, Hold or Sell?

Let's analyze Phaxiam together

I guess you are interested in PHAXIAM Therapeutics S.A.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of PHAXIAM Therapeutics S.A.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about PHAXIAM Therapeutics S.A.

I send you an email if I find something interesting about PHAXIAM Therapeutics S.A..

1. Quick Overview

1.1. Quick analysis of Phaxiam (30 sec.)










1.2. What can you expect buying and holding a share of Phaxiam? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€2.56
Expected worth in 1 year
€3.41
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€0.85
Return On Investment
51.8%

For what price can you sell your share?

Current Price per Share
€1.64
Expected price per share
€1.5 - €1.97
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Phaxiam (5 min.)




Live pricePrice per Share (EOD)
€1.64
Intrinsic Value Per Share
€-40.51 - €12.55
Total Value Per Share
€-37.95 - €15.11

2.2. Growth of Phaxiam (5 min.)




Is Phaxiam growing?

Current yearPrevious yearGrowGrow %
How rich?$27m$24.7m$2.2m8.3%

How much money is Phaxiam making?

Current yearPrevious yearGrowGrow %
Making money-$24.7m-$240.3k-$24.5m-99.0%
Net Profit Margin-1,771.3%-3.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Phaxiam (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Phaxiam?

Welcome investor! Phaxiam's management wants to use your money to grow the business. In return you get a share of Phaxiam.

First you should know what it really means to hold a share of Phaxiam. And how you can make/lose money.

Speculation

The Price per Share of Phaxiam is €1.638. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Phaxiam.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Phaxiam, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €2.56. Based on the TTM, the Book Value Change Per Share is €0.21 per quarter. Based on the YOY, the Book Value Change Per Share is €0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Phaxiam.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-2.47-151.0%-2.47-151.0%-0.02-1.5%-4.50-274.4%-3.49-212.8%
Usd Book Value Change Per Share0.2213.7%0.2213.7%0.074.1%-2.53-154.3%0.137.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.2213.7%0.2213.7%0.074.1%-2.53-154.3%0.137.7%
Usd Price Per Share4.85-4.85-0.39-4.41-11.82-
Price to Earnings Ratio-1.96--1.96--16.11--4.10--8.16-
Price-to-Total Gains Ratio21.68-21.68-5.72-3.87-4.18-
Price to Book Ratio1.80-1.80-0.16-1.27-2.47-
Price-to-Total Gains Ratio21.68-21.68-5.72-3.87-4.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.7269434
Number of shares579
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.22-2.53
Usd Total Gains Per Share0.22-2.53
Gains per Quarter (579 shares)129.54-1,462.96
Gains per Year (579 shares)518.17-5,851.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105185080-5852-5862
20103610260-11704-11714
30155515440-17555-17566
40207320620-23407-23418
50259125800-29259-29270
60310930980-35111-35122
70362736160-40963-40974
80414541340-46815-46826
90466446520-52666-52678
100518251700-58518-58530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.02.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%5.05.00.050.0%7.07.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.014.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%2.03.00.040.0%5.05.00.050.0%7.07.00.050.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of PHAXIAM Therapeutics S.A. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2120.2120%0.064+231%-2.397+1229%0.120+77%
Book Value Per Share--2.5582.5580%2.346+9%3.676-30%6.288-59%
Current Ratio--1.0631.0630%3.651-71%2.502-58%6.150-83%
Debt To Asset Ratio--0.5010.5010%0.487+3%0.519-3%0.323+55%
Debt To Equity Ratio--1.0031.0030%0.950+6%1.258-20%0.704+42%
Dividend Per Share----0%-0%-0%-0%
Eps---2.346-2.3460%-0.023-99%-4.264+82%-3.306+41%
Free Cash Flow Per Share---2.461-2.4610%-3.203+30%-4.613+87%-3.523+43%
Free Cash Flow To Equity Per Share---2.832-2.8320%-3.357+19%-3.299+16%-0.457-84%
Gross Profit Margin--1.1581.1580%5.592-79%1.957-41%1.479-22%
Intrinsic Value_10Y_max--12.551--------
Intrinsic Value_10Y_min---40.505--------
Intrinsic Value_1Y_max---2.498--------
Intrinsic Value_1Y_min---4.519--------
Intrinsic Value_3Y_max---4.643--------
Intrinsic Value_3Y_min---13.261--------
Intrinsic Value_5Y_max---3.337--------
Intrinsic Value_5Y_min---21.586--------
Market Cap16402113.000-181%46062100.00046062100.0000%3672951.800+1154%41850021.360+10%112238117.180-59%
Net Profit Margin---17.713-17.7130%-0.034-100%-12.439-30%-9.614-46%
Operating Margin---18.505-18.5050%0.026-72033%-12.944-30%-10.235-45%
Operating Ratio--20.05620.0560%4.827+316%14.409+39%10.968+83%
Pb Ratio0.640-181%1.7981.7980%0.156+1050%1.270+42%2.467-27%
Pe Ratio-0.698+64%-1.961-1.9610%-16.109+721%-4.101+109%-8.164+316%
Price Per Share1.638-181%4.6004.6000%0.367+1154%4.179+10%11.209-59%
Price To Free Cash Flow Ratio-0.666+64%-1.869-1.8690%-0.115-94%-0.949-49%-7.271+289%
Price To Total Gains Ratio7.719-181%21.67621.6760%5.721+279%3.865+461%4.176+419%
Quick Ratio--1.0051.0050%3.546-72%2.426-59%4.461-77%
Return On Assets---0.458-0.4580%-0.005-99%-0.542+18%-0.410-10%
Return On Equity---0.917-0.9170%-0.010-99%-1.355+48%-0.841-8%
Total Gains Per Share--0.2120.2120%0.064+231%-2.397+1229%0.120+77%
Usd Book Value--27002731.60027002731.6000%24762344.100+9%38807307.191-30%66384874.991-59%
Usd Book Value Change Per Share--0.2240.2240%0.068+231%-2.527+1229%0.127+77%
Usd Book Value Per Share--2.6972.6970%2.473+9%3.875-30%6.630-59%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.473-2.4730%-0.024-99%-4.495+82%-3.485+41%
Usd Free Cash Flow---25983223.500-25983223.5000%-33813509.600+30%-48705286.240+87%-37192643.473+43%
Usd Free Cash Flow Per Share---2.595-2.5950%-3.377+30%-4.864+87%-3.714+43%
Usd Free Cash Flow To Equity Per Share---2.986-2.9860%-3.539+19%-3.478+16%-0.482-84%
Usd Market Cap17292747.736-181%48563272.03048563272.0300%3872393.083+1154%44122477.520+10%118332646.943-59%
Usd Price Per Share1.727-181%4.8504.8500%0.387+1154%4.406+10%11.817-59%
Usd Profit---24763398.400-24763398.4000%-240380.400-99%-45012705.920+82%-34909036.525+41%
Usd Revenue--1398001.8001398001.8000%7007932.100-80%4460532.229-69%3988100.505-65%
Usd Total Gains Per Share--0.2240.2240%0.068+231%-2.527+1229%0.127+77%
 EOD+2 -6MRQTTM+0 -0YOY+17 -175Y+21 -1310Y+13 -21

3.3 Fundamental Score

Let's check the fundamental score of PHAXIAM Therapeutics S.A. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.698
Price to Book Ratio (EOD)Between0-10.640
Net Profit Margin (MRQ)Greater than0-17.713
Operating Margin (MRQ)Greater than0-18.505
Quick Ratio (MRQ)Greater than11.005
Current Ratio (MRQ)Greater than11.063
Debt to Asset Ratio (MRQ)Less than10.501
Debt to Equity Ratio (MRQ)Less than11.003
Return on Equity (MRQ)Greater than0.15-0.917
Return on Assets (MRQ)Greater than0.05-0.458
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of PHAXIAM Therapeutics S.A. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.414
Ma 20Greater thanMa 501.732
Ma 50Greater thanMa 1001.729
Ma 100Greater thanMa 2001.799
OpenGreater thanClose1.668
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Fundamental data was last updated by Penke on 2024-11-16 16:42:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Phaxiam earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Phaxiam to the Biotechnology industry mean.
  • A Net Profit Margin of -1,771.3% means that €-17.71 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is -1,771.3%. The company is making a huge loss. -2
  • The TTM is -1,771.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,771.3%TTM-1,771.3%0.0%
TTM-1,771.3%YOY-3.4%-1,767.9%
TTM-1,771.3%5Y-1,243.9%-527.5%
5Y-1,243.9%10Y-961.4%-282.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,771.3%-124.9%-1,646.4%
TTM-1,771.3%-208.9%-1,562.4%
YOY-3.4%-207.8%+204.4%
5Y-1,243.9%-351.9%-892.0%
10Y-961.4%-473.1%-488.3%
4.3.1.2. Return on Assets

Shows how efficient Phaxiam is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Phaxiam to the Biotechnology industry mean.
  • -45.8% Return on Assets means that Phaxiam generated €-0.46 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is -45.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -45.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.8%TTM-45.8%0.0%
TTM-45.8%YOY-0.5%-45.3%
TTM-45.8%5Y-54.2%+8.4%
5Y-54.2%10Y-41.0%-13.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.8%-10.7%-35.1%
TTM-45.8%-11.7%-34.1%
YOY-0.5%-11.2%+10.7%
5Y-54.2%-12.6%-41.6%
10Y-41.0%-14.4%-26.6%
4.3.1.3. Return on Equity

Shows how efficient Phaxiam is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Phaxiam to the Biotechnology industry mean.
  • -91.7% Return on Equity means Phaxiam generated €-0.92 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is -91.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -91.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-91.7%TTM-91.7%0.0%
TTM-91.7%YOY-1.0%-90.7%
TTM-91.7%5Y-135.5%+43.8%
5Y-135.5%10Y-84.1%-51.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91.7%-13.8%-77.9%
TTM-91.7%-15.8%-75.9%
YOY-1.0%-13.6%+12.6%
5Y-135.5%-18.6%-116.9%
10Y-84.1%-19.1%-65.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of PHAXIAM Therapeutics S.A..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Phaxiam is operating .

  • Measures how much profit Phaxiam makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Phaxiam to the Biotechnology industry mean.
  • An Operating Margin of -1,850.5% means the company generated €-18.51  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is -1,850.5%. The company is operating very inefficient. -2
  • The TTM is -1,850.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,850.5%TTM-1,850.5%0.0%
TTM-1,850.5%YOY2.6%-1,853.1%
TTM-1,850.5%5Y-1,294.4%-556.1%
5Y-1,294.4%10Y-1,023.5%-270.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,850.5%-258.6%-1,591.9%
TTM-1,850.5%-304.6%-1,545.9%
YOY2.6%-223.5%+226.1%
5Y-1,294.4%-389.5%-904.9%
10Y-1,023.5%-497.7%-525.8%
4.3.2.2. Operating Ratio

Measures how efficient Phaxiam is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 20.06 means that the operating costs are €20.06 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is 20.056. The company is inefficient in keeping operating costs low. -1
  • The TTM is 20.056. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ20.056TTM20.0560.000
TTM20.056YOY4.827+15.229
TTM20.0565Y14.409+5.647
5Y14.40910Y10.968+3.441
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.0562.760+17.296
TTM20.0563.393+16.663
YOY4.8273.299+1.528
5Y14.4094.814+9.595
10Y10.9686.536+4.432
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of PHAXIAM Therapeutics S.A..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Phaxiam is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.06 means the company has €1.06 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is 1.063. The company is just able to pay all its short-term debts.
  • The TTM is 1.063. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.063TTM1.0630.000
TTM1.063YOY3.651-2.588
TTM1.0635Y2.502-1.439
5Y2.50210Y6.150-3.648
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0633.709-2.646
TTM1.0633.886-2.823
YOY3.6514.684-1.033
5Y2.5025.946-3.444
10Y6.1506.274-0.124
4.4.3.2. Quick Ratio

Measures if Phaxiam is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Phaxiam to the Biotechnology industry mean.
  • A Quick Ratio of 1.00 means the company can pay off €1.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is 1.005. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.005. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.005TTM1.0050.000
TTM1.005YOY3.546-2.541
TTM1.0055Y2.426-1.421
5Y2.42610Y4.461-2.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0053.199-2.194
TTM1.0053.497-2.492
YOY3.5464.549-1.003
5Y2.4265.897-3.471
10Y4.4616.437-1.976
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of PHAXIAM Therapeutics S.A..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Phaxiam assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Phaxiam to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.50 means that Phaxiam assets are financed with 50.1% credit (debt) and the remaining percentage (100% - 50.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is 0.501. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.501. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.501TTM0.5010.000
TTM0.501YOY0.487+0.014
TTM0.5015Y0.519-0.018
5Y0.51910Y0.323+0.195
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5010.350+0.151
TTM0.5010.347+0.154
YOY0.4870.312+0.175
5Y0.5190.365+0.154
10Y0.3230.382-0.059
4.5.4.2. Debt to Equity Ratio

Measures if Phaxiam is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Phaxiam to the Biotechnology industry mean.
  • A Debt to Equity ratio of 100.3% means that company has €1.00 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PHAXIAM Therapeutics S.A.:

  • The MRQ is 1.003. The company is able to pay all its debts with equity. +1
  • The TTM is 1.003. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.003TTM1.0030.000
TTM1.003YOY0.950+0.053
TTM1.0035Y1.258-0.255
5Y1.25810Y0.704+0.554
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0030.393+0.610
TTM1.0030.437+0.566
YOY0.9500.374+0.576
5Y1.2580.450+0.808
10Y0.7040.493+0.211
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Phaxiam generates.

  • Above 15 is considered overpriced but always compare Phaxiam to the Biotechnology industry mean.
  • A PE ratio of -1.96 means the investor is paying €-1.96 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PHAXIAM Therapeutics S.A.:

  • The EOD is -0.698. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.961. Based on the earnings, the company is expensive. -2
  • The TTM is -1.961. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.698MRQ-1.961+1.263
MRQ-1.961TTM-1.9610.000
TTM-1.961YOY-16.109+14.148
TTM-1.9615Y-4.101+2.140
5Y-4.10110Y-8.164+4.063
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.698-2.225+1.527
MRQ-1.961-2.362+0.401
TTM-1.961-3.066+1.105
YOY-16.109-3.335-12.774
5Y-4.101-6.032+1.931
10Y-8.164-6.575-1.589
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PHAXIAM Therapeutics S.A.:

  • The EOD is -0.666. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.869. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.869. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.666MRQ-1.869+1.203
MRQ-1.869TTM-1.8690.000
TTM-1.869YOY-0.115-1.755
TTM-1.8695Y-0.949-0.920
5Y-0.94910Y-7.271+6.322
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.666-3.073+2.407
MRQ-1.869-3.177+1.308
TTM-1.869-3.575+1.706
YOY-0.115-4.527+4.412
5Y-0.949-8.367+7.418
10Y-7.271-9.230+1.959
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Phaxiam is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.80 means the investor is paying €1.80 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of PHAXIAM Therapeutics S.A.:

  • The EOD is 0.640. Based on the equity, the company is cheap. +2
  • The MRQ is 1.798. Based on the equity, the company is underpriced. +1
  • The TTM is 1.798. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.640MRQ1.798-1.158
MRQ1.798TTM1.7980.000
TTM1.798YOY0.156+1.642
TTM1.7985Y1.270+0.528
5Y1.27010Y2.467-1.197
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6401.893-1.253
MRQ1.7982.003-0.205
TTM1.7982.302-0.504
YOY0.1562.390-2.234
5Y1.2703.666-2.396
10Y2.4674.354-1.887
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Debt  -59,08742,054-17,0333,390-13,643-11,619-25,26228,0532,791



6.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets51,307
Total Liabilities25,695
Total Stockholder Equity25,612
 As reported
Total Liabilities 25,695
Total Stockholder Equity+ 25,612
Total Assets = 51,307

Assets

Total Assets51,307
Total Current Assets16,219
Long-term Assets35,088
Total Current Assets
Cash And Cash Equivalents 10,474
Net Receivables 4,864
Inventory -4,955
Other Current Assets 5,836
Total Current Assets  (as reported)16,219
Total Current Assets  (calculated)16,219
+/-0
Long-term Assets
Property Plant Equipment 3,899
Goodwill 9,622
Intangible Assets 21,362
Long-term Assets Other 205
Long-term Assets  (as reported)35,088
Long-term Assets  (calculated)35,088
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities15,264
Long-term Liabilities10,431
Total Stockholder Equity25,612
Total Current Liabilities
Short-term Debt 3,887
Accounts payable 3,678
Other Current Liabilities 7,699
Total Current Liabilities  (as reported)15,264
Total Current Liabilities  (calculated)15,264
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)10,431
Long-term Liabilities  (calculated)0
+/- 10,431
Total Stockholder Equity
Common Stock6,075
Retained Earnings -23,488
Accumulated Other Comprehensive Income -6,646
Other Stockholders Equity 49,671
Total Stockholder Equity (as reported)25,612
Total Stockholder Equity (calculated)25,612
+/-0
Other
Cash and Short Term Investments 10,474
Common Stock Shares Outstanding 4,695
Current Deferred Revenue4,144
Liabilities and Stockholders Equity 51,307
Net Debt 2,791
Net Working Capital 955
Short Long Term Debt Total 13,265



6.3. Balance Sheets Structured

All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
6,564
4,941
10,144
17,949
40,607
53,004
44,967
195,261
167,840
118,546
80,402
66,768
45,811
51,307
51,30745,81166,76880,402118,546167,840195,26144,96753,00440,60717,94910,1444,9416,564
   > Total Current Assets 
0
0
9,139
17,039
39,526
51,929
42,533
191,568
149,907
81,583
49,632
40,048
42,634
16,219
16,21942,63440,04849,63281,583149,907191,56842,53351,92939,52617,0399,13900
       Cash And Cash Equivalents 
3,174
2,229
7,875
15,113
36,988
45,634
37,646
174,525
134,371
73,173
44,446
33,699
38,789
10,474
10,47438,78933,69944,44673,173134,371174,52537,64645,63436,98815,1137,8752,2293,174
       Short-term Investments 
0
0
0
0
0
0
0
11,000
0
13
8
479
43
0
043479813011,0000000000
       Net Receivables 
1,701
1,193
999
1,687
2,123
5,910
4,402
4,540
9,679
5,823
4,334
4,709
2,576
4,864
4,8642,5764,7094,3345,8239,6794,5404,4025,9102,1231,6879991,1931,701
       Inventory 
91
98
116
138
198
166
145
176
1,396
386
0
0
0
-4,955
-4,9550003861,3961761451661981381169891
   > Long-term Assets 
0
0
1,005
910
1,080
1,075
2,434
3,693
17,933
36,963
30,770
26,720
3,177
35,088
35,0883,17726,72030,77036,96317,9333,6932,4341,0751,0809101,00500
       Property Plant Equipment 
1,201
1,015
771
813
967
918
2,245
3,406
15,274
35,641
29,090
25,829
2,977
3,899
3,8992,97725,82929,09035,64115,2743,4062,2459189678137711,0151,201
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
9,622
9,6220000000000000
       Long Term Investments 
0
0
0
0
0
0
0
66
91
17
17
0
0
0
000171791660000000
       Intangible Assets 
69
49
30
14
31
62
57
54
1,613
603
589
15
5
21,362
21,3625155896031,6135457623114304969
       Long-term Assets Other 
0
0
120
20
82
96
133
119
2,659
702
1,074
818
193
205
2051938181,0747022,65911913396822012000
> Total Liabilities 
2,578
6,847
14,171
4,362
4,782
5,872
9,329
13,842
22,238
32,986
53,863
43,923
22,324
25,695
25,69522,32443,92353,86332,98622,23813,8429,3295,8724,7824,36214,1716,8472,578
   > Total Current Liabilities 
1,696
1,683
7,477
3,515
4,258
5,621
6,347
11,606
20,648
19,881
29,347
20,005
11,678
15,264
15,26411,67820,00529,34719,88120,64811,6066,3475,6214,2583,5157,4771,6831,696
       Short-term Debt 
0
0
0
1,012
258
501
2,866
824
776
1,487
3,872
1,981
3,340
3,887
3,8873,3401,9813,8721,4877768242,8665012581,012000
       Short Long Term Debt 
0
0
0
1,012
258
501
2,866
746
738
100
2,265
164
2,565
0
02,5651642,2651007387462,8665012581,012000
       Accounts payable 
811
712
1,274
1,421
2,085
3,275
3,547
4,966
13,402
5,074
4,706
2,485
1,562
3,678
3,6781,5622,4854,7065,07413,4024,9663,5473,2752,0851,4211,274712811
       Other Current Liabilities 
729
816
1,575
1,812
1,840
51
-7
5,816
6,454
13,259
16,472
11,730
6,725
7,699
7,6996,72511,73016,47213,2596,4545,816-7511,8401,8121,575816729
   > Long-term Liabilities 
0
0
6,694
848
525
251
2,982
2,236
1,590
13,105
24,516
23,918
10,646
10,431
10,43110,64623,91824,51613,1051,5902,2362,9822515258486,69400
       Long term Debt Total 
0
0
0
0
0
0
1,634
837
62
11,278
19,155
18,113
10,227
0
010,22718,11319,15511,278628371,634000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-1,012
-258
-501
-2,662
-706
-737
11,216
6,932
7,998
115
-3,887
-3,8871157,9986,93211,216-737-706-2,662-501-258-1,012000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
-2
-1
1
0
0
1
0
01001-1-20000000
       Deferred Long Term Liability 
0
0
0
0
0
0
3
4
0
0
0
0
0
0
00000043000000
> Total Stockholder Equity
3,986
0
0
13,587
35,824
47,132
35,638
181,419
145,602
85,560
26,539
22,845
23,487
25,612
25,61223,48722,84526,53985,560145,602181,41935,63847,13235,82413,587003,986
   Common Stock
315
315
315
551
688
792
873
1,794
1,794
1,794
2,006
3,102
3,102
6,075
6,0753,1023,1022,0061,7941,7941,794873792688551315315315
   Retained Earnings Total Equity00000000000000
   Accumulated Other Comprehensive Income -6,646-28,590-77,875-96,172-197,922-137,937-102,120-2,439-2,041-1,771-1,530-1,29500
   Capital Surplus 
0
0
0
0
0
0
105,090
281,745
281,745
281,688
120,705
97,618
48,975
0
048,97597,618120,705281,688281,745281,745105,090000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
0
0
0
-21,560
-28,431
-34,578
-48,412
281,745
281,745
283,482
120,705
97,618
48,975
49,671
49,67148,97597,618120,705283,482281,745281,745-48,412-34,578-28,431-21,560000



6.4. Balance Sheets

All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,326
Cost of Revenue-1,608
Gross Profit1,326-282
 
Operating Income (+$)
Gross Profit1,326
Operating Expense-24,986
Operating Income-23,660-23,660
 
Operating Expense (+$)
Research Development10,910
Selling General Administrative10,263
Selling And Marketing Expenses3,703
Operating Expense24,98624,876
 
Net Interest Income (+$)
Interest Income3,508
Interest Expense-196
Other Finance Cost-3,325
Net Interest Income-13
 
Pretax Income (+$)
Operating Income-23,660
Net Interest Income-13
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,734-22,586
EBIT - interestExpense = -24,734
-24,734
-23,292
Interest Expense196
Earnings Before Interest and Taxes (EBIT)-24,538-24,538
Earnings Before Interest and Taxes (EBITDA)-22,930
 
After tax Income (+$)
Income Before Tax-24,734
Tax Provision--3,525
Net Income From Continuing Ops-11,957-21,209
Net Income-23,488
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses24,986
Total Other Income/Expenses Net-1,07413
 

Technical Analysis of Phaxiam
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Phaxiam. The general trend of Phaxiam is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Phaxiam's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of PHAXIAM Therapeutics S.A..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.96 < 1.96 < 1.97.

The bearish price targets are: 1.56 > 1.5.

Tweet this
PHAXIAM Therapeutics S.A. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of PHAXIAM Therapeutics S.A.. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

PHAXIAM Therapeutics S.A. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of PHAXIAM Therapeutics S.A.. The current macd is -0.00721986.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Phaxiam price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Phaxiam. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Phaxiam price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
PHAXIAM Therapeutics S.A. Daily Moving Average Convergence/Divergence (MACD) ChartPHAXIAM Therapeutics S.A. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of PHAXIAM Therapeutics S.A.. The current adx is 25.22.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Phaxiam shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
PHAXIAM Therapeutics S.A. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of PHAXIAM Therapeutics S.A.. The current sar is 2.1335.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
PHAXIAM Therapeutics S.A. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of PHAXIAM Therapeutics S.A.. The current rsi is 40.41. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
PHAXIAM Therapeutics S.A. Daily Relative Strength Index (RSI) ChartPHAXIAM Therapeutics S.A. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of PHAXIAM Therapeutics S.A.. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Phaxiam price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
PHAXIAM Therapeutics S.A. Daily Stochastic Oscillator ChartPHAXIAM Therapeutics S.A. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of PHAXIAM Therapeutics S.A.. The current cci is -91.00539528.

PHAXIAM Therapeutics S.A. Daily Commodity Channel Index (CCI) ChartPHAXIAM Therapeutics S.A. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of PHAXIAM Therapeutics S.A.. The current cmo is -27.28728835.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
PHAXIAM Therapeutics S.A. Daily Chande Momentum Oscillator (CMO) ChartPHAXIAM Therapeutics S.A. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of PHAXIAM Therapeutics S.A.. The current willr is -86.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
PHAXIAM Therapeutics S.A. Daily Williams %R ChartPHAXIAM Therapeutics S.A. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of PHAXIAM Therapeutics S.A..

PHAXIAM Therapeutics S.A. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of PHAXIAM Therapeutics S.A.. The current atr is 0.1017485.

PHAXIAM Therapeutics S.A. Daily Average True Range (ATR) ChartPHAXIAM Therapeutics S.A. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of PHAXIAM Therapeutics S.A.. The current obv is 1,256,478.

PHAXIAM Therapeutics S.A. Daily On-Balance Volume (OBV) ChartPHAXIAM Therapeutics S.A. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of PHAXIAM Therapeutics S.A.. The current mfi is 61.43.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
PHAXIAM Therapeutics S.A. Daily Money Flow Index (MFI) ChartPHAXIAM Therapeutics S.A. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for PHAXIAM Therapeutics S.A..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-07-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

PHAXIAM Therapeutics S.A. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of PHAXIAM Therapeutics S.A. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.414
Ma 20Greater thanMa 501.732
Ma 50Greater thanMa 1001.729
Ma 100Greater thanMa 2001.799
OpenGreater thanClose1.668
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Phaxiam with someone you think should read this too:
  • Are you bullish or bearish on Phaxiam? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Phaxiam? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about PHAXIAM Therapeutics S.A.

I send you an email if I find something interesting about PHAXIAM Therapeutics S.A..


Comments

How you think about this?

Leave a comment

Stay informed about PHAXIAM Therapeutics S.A..

Receive notifications about PHAXIAM Therapeutics S.A. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.